title: Influence of the location and number of metastases in the survival of metastatic prostatic cancer patients.
abstract: BACKGROUND
  The prognosis of patients diagnosed with metastatic prostate cancer seems to be modulated by factors such as the number and site of metastases. Our objective is to evaluate survival outcomes according to the number and site of metastases in our series of metastatic patients over the last 15 years.
  
  
  METHODS
  A retrospective analysis was performed on patients diagnosed between 1998 and 2014. We analyzed overall survival and progression-free survival, depending on the number and location of metastases on patients with newly diagnosed metastatic prostate cancer. Other potential prognostic factors were also evaluated: age, clinical stage, PSA at diagnosis, Gleason, PSA nadir, time till PSA nadir and first-line or second-line treatment after progression.
  
  
  RESULTS
  We analyzed a series of 162 patients. The mean age was 72.7yr (SD: 8.5). The estimated median overall survival was 3.9 yr (95% CI 2.6-5.2). The overall survival in patients with only lymph node metastases was 7 yr (95% CI 4.1-9.7), 3.9 (95%CI 2.3-5.5) in patients with only bone metastases, 2.5 yr (95% CI 2-2.3) in lymph nodes and bone metastases, and 2.2 yr (95% CI 1.4-3) in patients with visceral metastases (P<.001). In multivariate analysis, the location of metastasesis significantly associated with overall survival and progression-free survival. The number of metastases showed no association with survival.
  
  
  CONCLUSIONS
  The site of metastases has a clear impact on both overall survival and progression-free survival. Patients with only lymph node involvement had a better prognosis. The number of metastases showed no significant impact on survival in our series.
authors: Servicio de Urología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España. Electronic address: ana.guijarroc@gmail.com.
authors: A
authors: A
authors: Guijarro
authors: Servicio de Urología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España.
authors: V
authors: V
authors: Hernández
authors: Servicio de Urología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España.
authors: J M
authors: JM
authors: de la Morena
authors: Servicio de Urología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España.
authors: I
authors: I
authors: Jiménez-Valladolid
authors: Unidad de investigación, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España.
authors: E
authors: E
authors: Pérez-Fernández
authors: Servicio de Urología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España.
authors: E
authors: E
authors: de la Peña
authors: Servicio de Urología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España.
authors: C
authors: C
authors: Llorente
mesh_terms: D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000401:mortality* / Q000556:secondary*; D012189:Retrospective Studies; D015996:Survival Rate
keywords: Bone metastases; Cáncer de próstata; Lymph node metastases; Metástasis ganglionares; Metástasis viscerales; Metástasis óseas; Prostate cancer; Visceral metastases